-4.5%
AKAM vs MRNA
-67.9%
+63.4%
-46.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.3% | +5.4% | -5.7% | -0.5% |
| 7D | +1.5% | -1.1% | +2.6% | +1.5% |
| 30D | -13.0% | +126.1% | -139.1% | -18.7% |
| 3M | -19.4% | +190.0% | -209.4% | -27.5% |
| 6M | +0.3% | +157.2% | -156.9% | -8.7% |
| YTD | +22.4% | +388.2% | -365.8% | +3.4% |
| 1Y | +34.8% | +467.0% | -432.2% | +11.5% |
| 3Y | +1.9% | +36.1% | -34.1% | -7.3% |
| All | -4.5% | -67.9% | +63.4% | -7.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling